Takeda Pharmaceutical Company Limited (F:TKDA) — Market Cap & Net Worth
Market Cap & Net Worth: Takeda Pharmaceutical Company Limited (TKDA)
Takeda Pharmaceutical Company Limited (F:TKDA) has a market capitalization of $43.60 Billion (€37.29 Billion) as of September 8, 2026. Listed on the F stock exchange, this Germany-based company holds position #633 globally and #127 in its home market, demonstrating a 1.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Takeda Pharmaceutical Company Limited's stock price €15.90 by its total outstanding shares 3159192822 (3.16 Billion). Also see Takeda Pharmaceutical Company Limited assets under control for a full breakdown of the balance sheet.
Takeda Pharmaceutical Company Limited Market Cap History: 2019 to 2026
Takeda Pharmaceutical Company Limited's market capitalization history from 2019 to 2026. Data shows growth from $52.36 Billion to $58.73 Billion (2.57% CAGR). Also see TKDA cash flow conversion for how efficiently the company converts equity into cash flow.
Takeda Pharmaceutical Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Takeda Pharmaceutical Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Takeda Pharmaceutical Company Limited for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Takeda Pharmaceutical Company Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.45x
Takeda Pharmaceutical Company Limited's market cap is 0.45 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $52.36 Billion | $2.10 Trillion | $109.13 Billion | 0.02x | 0.48x |
| 2020 | $46.15 Billion | $3.29 Trillion | $44.24 Billion | 0.01x | 1.04x |
| 2021 | $39.47 Billion | $3.20 Trillion | $376.00 Billion | 0.01x | 0.10x |
| 2022 | $49.81 Billion | $3.57 Trillion | $230.06 Billion | 0.01x | 0.22x |
| 2023 | $45.47 Billion | $4.03 Trillion | $317.02 Billion | 0.01x | 0.14x |
| 2024 | $46.17 Billion | $4.26 Trillion | $144.07 Billion | 0.01x | 0.32x |
| 2025 | $48.75 Billion | $4.58 Trillion | $107.93 Billion | 0.01x | 0.45x |
Competitor Companies of TKDA by Market Capitalization
Companies near Takeda Pharmaceutical Company Limited in the global market cap rankings as of September 8, 2026. Review Takeda Pharmaceutical Company Limited tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Takeda Pharmaceutical Company Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #525 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #610 globally with a market cap of $45.51 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #638 globally with a market cap of $43.18 Billion USD ( CN¥295.09 Billion CNY).
- Haleon plc (NYSE:HLN): Ranked #648 globally with a market cap of $42.28 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #525 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #610 | GALDERMA GROUP AG | NYSE:GALDY | $45.51 Billion | $39.03 |
| #638 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.18 Billion | CN¥46.26 |
| #648 | Haleon plc | NYSE:HLN | $42.28 Billion | $9.60 |
Takeda Pharmaceutical Company Limited Historical Marketcap From 2019 to 2026
Between 2019 and today, Takeda Pharmaceutical Company Limited's market cap moved from $52.36 Billion to $ 58.73 Billion, with a yearly change of 2.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €58.73 Billion | +20.45% |
| 2025 | €48.75 Billion | +5.60% |
| 2024 | €46.17 Billion | +1.52% |
| 2023 | €45.47 Billion | -8.70% |
| 2022 | €49.81 Billion | +26.18% |
| 2021 | €39.47 Billion | -14.46% |
| 2020 | €46.15 Billion | -11.87% |
| 2019 | €52.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 8th, 2026 the market cap of Takeda Pharmaceutical Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.60 Billion USD |
| MoneyControl | $43.60 Billion USD |
| MarketWatch | $43.60 Billion USD |
| marketcap.company | $43.60 Billion USD |
| Reuters | $43.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more